Navigation Links
Oncolytics Biotech(R) Inc. Announces Second Quarter 2010 Results
Date:7/29/2010

Period Period Period Ending June Ending June Ending June 30, 2010 30, 2009 30, 2010 $ $ $ ------------------------------------------------------------------------- Revenue Rights revenue - - - ------------------------------------------------------------------------- - - - Expenses Research and development 3,561,168 3,239,210 6,400,481 Operating 1,133,319 980,721 2,082,743 Stock based compensation 1,399 8,544 2,428 Foreign exchange loss/(gain) (349,229) 3,103 (2,850) Amortization - intellectual property - 90,375 - Amortization - property and equipment 14,621 16,536 29,506 ------------------------------------------------------------------------- 4,361,278 4,338,489 8,512,308 ------------------------------------------------------------------------- Loss before the following: 4,361,278 4,338,489 8,512,308 Interest income (9,304) (3,732) (19,123) Gain on sale of BCY LifeSciences Inc. - - - Loss on sale of Transition Therapeutics Inc. - - - ------------------------------------------------------------------------- Loss before income taxes 4,351,974 4,334,757 8,493,185 Future income tax recovery - - - ------------------------------------------------------
'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Oncolytics Biotech(R) Inc. Announces Issuance of 35th U.S. Patent
2. Oncolytics Biotech(R) Inc. To Host Conference Call to Discuss Updated U.K. Phase I/II Trial Head and Neck Cancer Data Being Presented at the ASCO Annual Meeting
3. Oncolytics Biotech(R) Inc. Receives Approval from Belgium FAMHP to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
4. Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Pancreatic Cancer Clinical Trial
5. Oncolytics Biotech(R) Inc. Announces Opening of Enrollment in Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
6. Oncolytics Biotech(R) Inc. Announces Reovirus Research to be Presented at ASCO Annual Meeting
7. Oncolytics Biotech(R) Inc. Announces Phase I Colorectal Cancer Study
8. Oncolytics Biotech(R) Inc. Announces Publication of Phase I Clinical Trial Results in Clinical Cancer Research
9. Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results
10. Oncolytics Biotech(R) Inc. Announces Details of 2010 Annual Shareholder Meeting
11. Oncolytics Biotech(R) Inc. Completes Patient Enrollment in Phase I Portion of U.S. Phase I/II Recurrent Malignant Gliomas Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Sigma-Aldrich Corporation (NASDAQ: SIAL ... the Hart-Scott-Rodino Antitrust Improvements Act (HSR Act) in ... 2014, thereby completing the U.S. HSR Act antitrust ... the Company by Merck KGaA, Darmstadt, Germany.  ... to closing the transaction, which remains subject to ...
(Date:12/22/2014)... Malvern, PA & Brussels (PRWEB) December 22, 2014 ... Education (CfPIE), the global leader of technical training ... Society for Clinical Data Management (SCDM) to ... training and certification programs —providing access to the ... The partnership extends SCDM members with 10% off when ...
(Date:12/22/2014)... , Dec. 22, 2014  Alternative Energy & ... it has signed a letter of intent to ... developed and patented a nanotechnology-based development platform used ... that enable rapid on-site collection and testing to ... health issues in an immediate, non-invasive and cost-effective ...
(Date:12/22/2014)... The American Journal of Hematology/Oncology, ... reviews and editorials addressing developments and pathways related ... a provocative article exploring the role of follicle-stimulating ... treatment of prostate cancer. , The article ... possibility that there could be a connection to ...
Breaking Biology Technology:Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3CfPIE Announces Partnership with the Society for Clinical Data Management 2CfPIE Announces Partnership with the Society for Clinical Data Management 3ALNE Announces Intention To Acquire BioTechPharma 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4
... - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ... completed in the Phase II component of a Phase ... patients with advanced cancers. The principal investigators for the ... Cancer Research, London, England, and Dr. Geoff Hall of ...
... materials scientists at the National Institute of Standards and ... in Russia to an unexpected findingthe surprisingly strong and ... storage. Their recently reported findings* may add new scientific ... density data storage devices. The team was studying ...
... 1 Johnson & Johnson ... Department of Molecular Biology at the Max Planck Institute ... novel cancer therapies including Herceptin(R) (trastuzumab)*, is the winner ... Research. An independent committee of world-renowned scientists selected Dr. ...
Cached Biology Technology:Oncolytics Biotech(R) Inc. Completes Patient Enrolment in U.K. Combination REOLYSIN(R) and Paclitaxel/Carboplatin Head and Neck Cancer Trial 2Unexpectedly long-range effects in advanced magnetic devices 2Video: Axel Ullrich Named Winner of 2009 Dr. Paul Janssen Award for Biomedical Research 2Video: Axel Ullrich Named Winner of 2009 Dr. Paul Janssen Award for Biomedical Research 3Video: Axel Ullrich Named Winner of 2009 Dr. Paul Janssen Award for Biomedical Research 4Video: Axel Ullrich Named Winner of 2009 Dr. Paul Janssen Award for Biomedical Research 5
(Date:12/22/2014)... , Dec. 22, 2014 Research ... has announced the addition of the ... report to their offering. ... insight provides an overview of the global ... aims to control and monitor piracy by ...
(Date:12/19/2014)... , Dec. 18, 2014   LaunchKey , ... for the post-password and Internet of Things era, today ... funding. The venture round was led by Metamorphic Ventures ... Rimrock Venture Partners, VegasTechFund, and others.  LaunchKey has raised ... funding to expand its team and bring LaunchKey to ...
(Date:12/17/2014)... Research and Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ... "Global Chemical Sensor Market 2015-2019" report to ... One major trend upcoming in ... sensors in biomedical applications. Chemical sensors help in ... diagnosis during surgical procedures. The Global Chemical Sensor ...
Breaking Biology News(10 mins):The Global Watermarking and Fingerprinting Markets 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2
... might call "white graphene" may be the perfect sidekick ... in nanoscale electronics. But single-atom-thick layers of hexagonal ... Rice University,s world-class Department of Mechanical Engineering and Materials ... well. Researchers in the lab of Pulickel Ajayan, ...
... hardest workers as key pollinators for one-third of all ... half-century, with die-offs in recent years stumping scientists and ... Science Foundation (NSF) multi-institutional grant co-led by Cornell ... natural history bee collections across the United States. This ...
... Ecologists have long believed that fish tend to return to ... But researchers at Ohio State University have determined that the ... walleye, at least. Using a statistical analysis of chemicals ... calculate the percentage of walleye hatched in the Sandusky and ...
Cached Biology News:'White graphene' to the rescue 2New $1.5 million NSF grant to track bee declines and pollination 2Ear bones reveal spawning secrets of Lake Erie walleye 2Ear bones reveal spawning secrets of Lake Erie walleye 3Ear bones reveal spawning secrets of Lake Erie walleye 4
Anti-Chicken IgY, (IgG) F(ab')2 Fragment Specific....
Presenilin 2 Immunogen: Synthetic peptide corresponding to residues 31-47 of human Presenilin 2. Storage: -20 C, Avoid Freeze/Thaw Cycles...
SHP-2 Antibody...
200 μg per ml DNA in 10 SSPE, 2 Denhardt's...
Biology Products: